Piramal Critical Care and BrePco Biopharma received UK approval for Neoatricon, a paediatric Dopamine Hydrochloride solution.

Piramal Critical Care, a part of Piramal Pharma, and Ireland-based BrePco Biopharma have received marketing approval from the ...

Dopamine is an inotropic agent that has vasodilatory effects at low doses. It is a common belief that low-dose dopamine may be helpful in the prevention and treatment of acute renal failure and is ...

Developed by Ireland-based BrePco Biopharma, Neoatricon is the first paediatric-strength dopamine hydrochloride infusion for ...

Piramal Critical Care has reserved commercialisation rights for the EU, UK, and Norway and will look after Neoatricon in ...

The Food and Drug Administration (FDA) has approved Onapgo™ (apomorphine hydrochloride [HCl]) for ... a non-ergoline dopamine agonist, on a continuous basis. Apomorphine is believed to treat ...